Filing Flows › Integrated Biopharma (INBP) › Q2 FY25
Integrated Biopharma (INBP) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Feb 13, 2025
Integrated Biopharma (INBP) reported revenue of $12.6M for the second quarter fiscal 2025 (Q2 FY25), +10% from a year earlier and -7% from the quarter before. Operating margin was 1.6%, net earnings $116K (0.9% of revenue).
Integrated Biopharma, Q2 FY25: revenue $12.6M (+10% year over year), operating margin 1.6%, net earnings $116K, operating cash flow $201K. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.6M | -7% | +10% |
| Gross profit | $1.2M | -15% | +125% |
| Operating profit | $202K | -59% | — |
| Net earnings | $116K | -55% | — |
| Operating cash flow | $201K | -69% | — |
| Free cash flow | $172K | -71% | — |
What changed
Revenue was $12.6M in Q2 FY25, up 10% year over year and down 7% from the previous quarter. Contract Manufacturing was the largest line at 93% of revenue. Contract Manufacturing added $617K year over year (up 6%), 56% of the total change.
Gross margin was 9.3%, up 4.8 points from a year earlier. Operating profit was $202K, a 1.6% margin (up 5.5 points year over year). Operating expenses fell 0% while revenue rose 10%. Net earnings were $116K. The effective tax rate was 37.3%.
Operating cash flow was $201K, 173% of net earnings. Non-cash charges added back $83K of depreciation and $43K of share-based compensation. Working capital and other items used $41K. Capital expenditures of $29K left free cash flow of $172K.
Questions
What was Integrated Biopharma's revenue in the second quarter fiscal 2025?
Integrated Biopharma (INBP) reported revenue of $12.6M for the second quarter fiscal 2025 (Q2 FY25), +10% from a year earlier and -7% from the quarter before.
Was Integrated Biopharma profitable in the second quarter fiscal 2025?
Operating profit was $202K (1.6% of revenue) and net earnings $116K.